239 related articles for article (PubMed ID: 27993682)
1. Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.
Huynh FC; Nguyen D; Jones FE
Biochem Biophys Res Commun; 2017 Jan; 483(1):739-744. PubMed ID: 27993682
[TBL] [Abstract][Full Text] [Related]
2. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
4. The role of S6K1 in ER-positive breast cancer.
Holz MK
Cell Cycle; 2012 Sep; 11(17):3159-65. PubMed ID: 22895181
[TBL] [Abstract][Full Text] [Related]
5. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1.
Ben-Hur V; Denichenko P; Siegfried Z; Maimon A; Krainer A; Davidson B; Karni R
Cell Rep; 2013 Jan; 3(1):103-15. PubMed ID: 23273915
[TBL] [Abstract][Full Text] [Related]
6. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.
Huck B; Duss S; Hausser A; Olayioye MA
J Biol Chem; 2014 Feb; 289(6):3138-47. PubMed ID: 24337579
[TBL] [Abstract][Full Text] [Related]
7. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
Berns K; Sonnenblick A; Gennissen A; Brohée S; Hijmans EM; Evers B; Fumagalli D; Desmedt C; Loibl S; Denkert C; Neven P; Guo W; Zhang F; Knijnenburg TA; Bosse T; van der Heijden MS; Hindriksen S; Nijkamp W; Wessels LF; Joensuu H; Mills GB; Beijersbergen RL; Sotiriou C; Bernards R
Clin Cancer Res; 2016 Nov; 22(21):5238-5248. PubMed ID: 27172896
[TBL] [Abstract][Full Text] [Related]
8. mTORC1-S6K1 inhibition or mTORC2 activation improves hippocampal synaptic plasticity and learning in Angelman syndrome mice.
Sun J; Liu Y; Tran J; O'Neal P; Baudry M; Bi X
Cell Mol Life Sci; 2016 Nov; 73(22):4303-4314. PubMed ID: 27173058
[TBL] [Abstract][Full Text] [Related]
9. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
Ghosh J; Kapur R
Exp Hematol; 2017 Jun; 50():13-21. PubMed ID: 28342808
[TBL] [Abstract][Full Text] [Related]
10. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
11. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
12. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
[TBL] [Abstract][Full Text] [Related]
13. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.
Mohd Sharial MSN; Crown J; Hennessy BT
Ann Oncol; 2012 Dec; 23(12):3007-3016. PubMed ID: 22865781
[TBL] [Abstract][Full Text] [Related]
14. Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells.
Hirashita Y; Tsukamoto Y; Yanagihara K; Fumoto S; Hijiya N; Nakada C; Uchida T; Matsuura K; Kodama M; Okimoto T; Daa T; Seike M; Iha H; Shirao K; Murakami K; Moriyama M
Cancer Sci; 2016 Dec; 107(12):1919-1928. PubMed ID: 27699948
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
16. Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
Sharma A; Janocha AJ; Hill BT; Smith MR; Erzurum SC; Almasan A
Mol Cancer Res; 2014 Sep; 12(9):1205-15. PubMed ID: 25061101
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation.
Hong S; Zhao B; Lombard DB; Fingar DC; Inoki K
J Biol Chem; 2014 May; 289(19):13132-41. PubMed ID: 24652283
[TBL] [Abstract][Full Text] [Related]
18. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling.
Gao S; Duan C; Gao G; Wang X; Yang H
Int J Biochem Cell Biol; 2015 Jul; 64():25-33. PubMed ID: 25813876
[TBL] [Abstract][Full Text] [Related]
20. Leucine does not affect mechanistic target of rapamycin complex 1 assembly but is required for maximal ribosomal protein s6 kinase 1 activity in human skeletal muscle following resistance exercise.
Apró W; Moberg M; Hamilton DL; Ekblom B; Rooyackers O; Holmberg HC; Blomstrand E
FASEB J; 2015 Oct; 29(10):4358-73. PubMed ID: 26169935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
